Giuseppe Remuzzi

Valparaiso University — United States

Medicine · Health Sciences

202h-index339.7kcitations2.1kworks114.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal Diseases and Glomerulopathies(446), Chronic Kidney Disease and Diabetes(344), Complement system in diseases(275), Blood Pressure and Hypertension Studies(186), Renal Transplantation Outcomes and Treatments(165)

Publications2.0k total

Mitochondria to the Rescue: Organelle Trafficking in Renal Health and Disease
˜The œNephron journals/Nephron journals·2025
Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays
Kidney International Reports·2025Open Access
The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care
Clinical Journal of the American Society of Nephrology·2025
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
New England Journal of Medicine·2025· 8 cited
Still searching for the right target for cardioprotection in haemodialysis
Nature Reviews Nephrology·2025
Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis
European Heart Journal·2025· 2 citedOpen Access
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure
Nature Medicine·2025· 2 cited
Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and Anemia
American Journal of Nephrology·2025
Hierarchical clustering uncovered disease patterns and further untangled complexities in immune complex-mediated idiopathic MPGN and C3 glomerulopathy
Kidney International·2025· 3 citedOpen Access
#3391 Pegcetacoplan treatment appears to halt disease progression in C3G and primary (idiopathic) IC-MPGN patients: results from the phase 3 VALIANT study
Nephrology Dialysis Transplantation·2025· 1 citedOpen Access
Pegcetacoplan for 52 Weeks Results in Sustained Proteinuria Reduction to Remission (≤0.5 g/g) and Normalization (≤0.2 g/g): Phase 3 VALIANT Trial
Journal of the American Society of Nephrology·2025
#288 Pegcetacoplan demonstrates clinically significant responses in C3G and primary (idiopathic) IC-MPGN Patients with or without concomitant immunosuppression in VALIANT
Nephrology Dialysis Transplantation·2025· 1 cited
Pegcetacoplan for 52 Weeks Maintains Proteinuria Reduction Regardless of Immunosuppressant Use or Nephrotic-Range Proteinuria at Baseline: VALIANT Subgroup Analysis
Journal of the American Society of Nephrology·2025
Human Induced Pluripotent Stem Cell (iPSC)-Derived Glomerulus-on-a-Chip for Disease Modeling and Drug Testing
Journal of the American Society of Nephrology·2025
Thyroxine as a Pleiotropic Modulator in ADPKD: Insights from Engineered Tubules, In Vivo Models, and Patients
Journal of the American Society of Nephrology·2025
#1394 Endothelin-1 and cardio-kidney events among patients with CKD, diabetes, and anemia
Nephrology Dialysis Transplantation·2025Open Access
#3265 Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or primary (idiopathic) IC-MPGN
Nephrology Dialysis Transplantation·2025Open Access
#3018 Iptacopan's rapid and sustained inhibition of overactive complement alternative pathway in C3G: Exploratory analysis from the Phase 3 APPEAR-C3G study
Nephrology Dialysis Transplantation·2025Open Access
Thyroid Hormone Nanotherapy Improves Kidney Function and Structure in Diabetic Nephropathy
Journal of the American Society of Nephrology·2025
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study
The Lancet·2025· 12 citedOpen Access
page 1 of 99Next →

Frequent Co-authors

Dick de Zeeuw(8), Marina Noris(8), Piero Ruggenenti(8), Annalisa Perna(6), Mark E. Cooper(5), Hans‐Henrik Parving(5), Ariela Benigni(5), Barry M. Brenner(4), Marcello Tonelli(4), Norberto Perico(4), Carla Zoja(4), William F. Keane(3), William E. Mitch(3), Shahnaz Shahinfar(3), Andrea Remuzzi(3), Emmanuel A. Burdmann(3), Andrew S. Levey(3), John J.V. McMurray(3), Robert D. Toto(3), Vivekanand Jha(3)